CN101175531B - 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物 - Google Patents

包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物 Download PDF

Info

Publication number
CN101175531B
CN101175531B CN2006800164912A CN200680016491A CN101175531B CN 101175531 B CN101175531 B CN 101175531B CN 2006800164912 A CN2006800164912 A CN 2006800164912A CN 200680016491 A CN200680016491 A CN 200680016491A CN 101175531 B CN101175531 B CN 101175531B
Authority
CN
China
Prior art keywords
active substance
carveol
alone
antibiotic
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800164912A
Other languages
English (en)
Chinese (zh)
Other versions
CN101175531A (zh
Inventor
阿德南·雷梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Scientific Developments
Original Assignee
Advanced Scientific Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scientific Developments filed Critical Advanced Scientific Developments
Publication of CN101175531A publication Critical patent/CN101175531A/zh
Application granted granted Critical
Publication of CN101175531B publication Critical patent/CN101175531B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800164912A 2005-05-13 2006-05-15 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物 Active CN101175531B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/IB2005/001313 2005-05-13
PCT/IB2005/001313 WO2006120494A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol
PCT/IB2006/001350 WO2006120567A2 (fr) 2005-05-13 2006-05-15 Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201310230786.1A Division CN103356612B (zh) 2005-05-13 2006-05-15 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物
CN2011101912078A Division CN102319246B (zh) 2005-05-13 2006-05-15 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物

Publications (2)

Publication Number Publication Date
CN101175531A CN101175531A (zh) 2008-05-07
CN101175531B true CN101175531B (zh) 2011-09-07

Family

ID=35427275

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310230786.1A Active CN103356612B (zh) 2005-05-13 2006-05-15 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物
CN2006800164912A Active CN101175531B (zh) 2005-05-13 2006-05-15 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物
CN2011101912078A Active CN102319246B (zh) 2005-05-13 2006-05-15 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310230786.1A Active CN103356612B (zh) 2005-05-13 2006-05-15 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011101912078A Active CN102319246B (zh) 2005-05-13 2006-05-15 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物

Country Status (13)

Country Link
US (1) US20080214518A1 (enExample)
EP (1) EP1879655B1 (enExample)
JP (1) JP5410748B2 (enExample)
CN (3) CN103356612B (enExample)
BR (1) BRPI0610125B8 (enExample)
CA (1) CA2606875C (enExample)
DK (1) DK1879655T3 (enExample)
EA (1) EA014069B1 (enExample)
ES (1) ES2530963T3 (enExample)
MA (1) MA29606B1 (enExample)
PT (1) PT1879655E (enExample)
TN (1) TNSN07424A1 (enExample)
WO (2) WO2006120494A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918571B1 (fr) * 2007-07-10 2013-01-11 Aroma Tech Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
US10449247B2 (en) * 2007-10-26 2019-10-22 Avivagen Inc. Compositions and methods for enhancing immune response
FR2925334A1 (fr) * 2007-12-21 2009-06-26 Ceva Sante Animale Sa Nouvelles compositions antibacteriennes
AU2010242502B2 (en) 2009-04-30 2016-11-10 Avivagen Inc. Methods and compositions for improving the health of animals
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
EP2648681B1 (en) 2010-12-07 2015-01-07 Unilever N.V. An oral care composition
EP2773315B1 (en) 2011-11-03 2015-07-08 Unilever N.V. A personal cleaning composition
BR112014013601B1 (pt) 2011-12-06 2020-04-14 Unilever Nv composições antimicrobianas, método não terapêutico para desinfetar uma superfície e usos não terapêuticos de uma composição
CN102670598B (zh) * 2012-05-08 2014-07-16 广东药学院 一种青霉素冰片组合物在制备抗菌药物中的应用
CN102670619B (zh) * 2012-05-08 2014-02-19 广东药学院 一种头孢氨苄冰片组合物
CN103146255B (zh) * 2013-02-25 2014-07-09 厦门吉宏包装科技有限公司 一种抑菌驱螨印刷底油母液和由母液制作的印刷底油及其制备方法
EP2993985A4 (en) * 2013-05-07 2016-10-05 Kemin Ind Inc ANTIMICROBIAL COMPOSITIONS WITH CARVACROL AND THYMOL
FR3025718A1 (fr) 2014-09-15 2016-03-18 Septeos Antimicrobiens potentialises
FR3025719A1 (fr) 2014-09-15 2016-03-18 Septeos Antimicrobiens potentialises
US10780294B2 (en) 2014-11-19 2020-09-22 The General Hospital Corporation System and method for photo-dynamic procedure
DK3233105T3 (da) * 2014-12-18 2020-11-16 Helperby Therapeutics Ltd Hidtil ukendt kombination og anvendelse
CN107548303A (zh) * 2014-12-18 2018-01-05 赫尔普百治疗有限公司 抗微生物组合和其在治疗微生物感染中的用途
CN106377757B (zh) * 2016-03-04 2020-05-19 广州英赛特生物技术有限公司 含氧碳氢衍生物作为多粘菌素的协同增效剂的应用
FR3048612B1 (fr) 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
CN109562182A (zh) 2016-06-02 2019-04-02 先进科学发展公司 包含桉树脑和阿莫西林的药物制剂
GB201904963D0 (en) * 2019-04-08 2019-05-22 Anpario Plc Composition for reducing antimicrobial resistance
WO2021110915A1 (fr) 2019-12-04 2021-06-10 Pranarôm International S.A. Procede de transformation d'une huile essentielle
KR102848354B1 (ko) * 2023-02-13 2025-08-21 경상국립대학교산학협력단 테트라사이클린계 항생제와 시너지 효과를 가지는 바닐린 또는 카바크롤을 유효성분으로 포함하는 조성물 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308873A (en) * 1992-12-18 1994-05-03 Doyle E. Chastain Method of killing yeast and fungi with carveol
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317775A (en) * 1980-01-07 1982-03-02 Hoffmann-La Roche Inc. Amoxicillin derivatives
US5213615A (en) * 1986-10-11 1993-05-25 Ivoclar Ag Dental material and method for the control of caries and paradentitis
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
US5801153A (en) * 1991-09-13 1998-09-01 Badaway; Mohammed A. Method of enhancing the antimicrobial properties of antibacterial antibiotics to massively control and prevent bacterial, fungal, and viral diseases in plants
FR2697133B1 (fr) * 1992-10-28 1995-01-13 Transbiotech Composition biocide et/ou biostatique et ses applications.
EP0831870A4 (en) * 1995-06-07 1998-09-16 Avmax Inc USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6025400A (en) * 1998-08-24 2000-02-15 Marco Polo Technologies Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same
SE9901733L (sv) * 1999-05-12 2000-11-13 Akzo Nobel Nv En komposition innehållande karvakrol och tymol för användning som bactericid
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
US6495512B1 (en) * 2000-06-23 2002-12-17 International Flavors & Fragrances Inc. Salicylaldehyde-containing composition having antimicrobial and fragrancing properties and process for using same
WO2002028382A1 (en) * 2000-10-06 2002-04-11 Van Beek, Ron Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
US20030180349A1 (en) * 2001-12-07 2003-09-25 Franklin Lanny U. Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
EP1562543A1 (en) * 2002-11-21 2005-08-17 J.P.M.E.D. Ltd. Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
EA200500804A1 (ru) * 2002-12-10 2005-12-29 Биосинексус Инкорпорейтед Топические противоинфекционные композиции
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
EP2338332B1 (en) * 2004-05-20 2014-02-12 Eden Research Plc Hollow glucan particle or cell wall particle encapsulating a terpene component

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308873A (en) * 1992-12-18 1994-05-03 Doyle E. Chastain Method of killing yeast and fungi with carveol
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
CN1514712A (zh) * 2001-04-10 2004-07-21 ������ҩ�����޹�˾ 指甲用组合物及其施用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jia-You Fang, et al.Efficacy and irritancy of enhancers on the in-vitro and in-vivo percutaneous absorption of curcumin.《JOURNAL OF PHARMACY AND PHARMACOLOGY》.2003,第55卷第593-601页. *

Also Published As

Publication number Publication date
CN102319246B (zh) 2013-07-17
WO2006120494A1 (fr) 2006-11-16
US20080214518A1 (en) 2008-09-04
CA2606875A1 (fr) 2006-11-16
WO2006120567A2 (fr) 2006-11-16
EP1879655B1 (fr) 2014-11-26
MA29606B1 (fr) 2008-07-01
CN101175531A (zh) 2008-05-07
BRPI0610125A2 (pt) 2012-09-25
TNSN07424A1 (fr) 2009-03-17
ES2530963T3 (es) 2015-03-09
WO2006120567A3 (fr) 2007-08-23
BRPI0610125B1 (pt) 2020-08-11
EA014069B1 (ru) 2010-08-30
EA200702483A1 (ru) 2008-04-28
JP2008540507A (ja) 2008-11-20
CN103356612B (zh) 2015-04-15
DK1879655T3 (en) 2015-02-23
CA2606875C (fr) 2015-12-15
EP1879655A2 (fr) 2008-01-23
BRPI0610125B8 (pt) 2021-05-25
CN103356612A (zh) 2013-10-23
CN102319246A (zh) 2012-01-18
PT1879655E (pt) 2015-02-24
JP5410748B2 (ja) 2014-02-05

Similar Documents

Publication Publication Date Title
CN101175531B (zh) 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物
US11529361B2 (en) Halogenated salicylanilides for treating Clostridium infections
Durante-Mangoni et al. Do we still need the aminoglycosides?
JP2004339238A5 (enExample)
JP2002525335A (ja) 抗生剤の投与方法
MX2007010129A (es) Derivados de beta-ciclodextrina como agentes antibacteriales.
CN113939306A (zh) 用于治疗涉及生物膜的细菌感染的阿法比星
KR20070063036A (ko) 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물
EP1044006B1 (en) Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物
KR20140035376A (ko) 항균제 및 타조박탐을 포함하는 조성물
CN107073124A (zh) 增效的抗微生物剂
EP1790357B1 (en) Perorally administrable antimicrobial composition
WO2016081825A1 (en) Methods and compositions for treating clostridium difficile associated disease
JP6525999B2 (ja) 抗菌性組成物
CN106794250A (zh) 包含抗菌剂的药物组合物
KR20150038611A (ko) 백본-고리형 펩타이드와의 조합물
KR20160138304A (ko) 항균 물질들을 포함하는 약학 조성물
Huband et al. In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
US20190388437A1 (en) Compositions and methods for treating bone and joint infections
US20190209645A1 (en) Potentiation of antibiotic activity by a novel cationic peptide, spr741

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant